## Edgar Filing: VALEANT PHARMACEUTICALS INTERNATIONAL - Form 4

VALEANT PHARMACEUTICAI Form 4 May 26, 2005	S INTERNATIONAL				
<b>FORM 4</b> Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue	COMMISSION MRRSHIP OF ge Act of 1934, of 1935 or Section COMB APPROVAL OMB Sumber: Sepres: Comb Approval Sumber: Sepres: Sepres: Sumber: Sepres: Sepres: Sumber				
(Print or Type Responses)					
1. Name and Address of Reporting Persor THURMAN RANDY	<ul> <li>2. Issuer Name and Ticker or Trading Symbol</li> <li>VALEANT PHARMACEUTICALS INTERNATIONAL [VRX]</li> </ul>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable)			
(Last) (First) (Middle) 3300 HYLAND AVENUE	3. Date of Earliest Transaction (Month/Day/Year) 05/24/2005	X_ Director 10% Owner Officer (give title Other (specify below) below)			
(Street) COSTA MESA, CA 92626	4. If Amendment, Date Original Filed(Month/Day/Year)	<ul> <li>6. Individual or Joint/Group Filing(Check Applicable Line)</li> <li>_X_ Form filed by One Reporting Person</li> <li> Form filed by More than One Reporting Person</li> </ul>			
(City) (State) (Zip)	Table I - Non-Derivative Securities Ac	quired, Disposed of, or Beneficially Owned			
(Instr. 3) any (Mo	rution Date, if Transaction(A) or Disposed of (D) Code (Instr. 3, 4 and 5) nth/Day/Year) (Instr. 8) (A) or Code V Amount (D) Price	5. Amount of Securities6. Ownership Form: Direct7. Nature of IndirectBeneficially Owned(D) or Indirect (I)Beneficial OwnershipFollowing Following Transaction(s) (Instr. 3 and 4)(Instr. 4)			
Phantom 05/24/2005 stock	A $\frac{7,594}{(1)}$ A $\frac{$}{21.07}$	28,291 D			

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	4. Transactio Code (Instr. 8)	of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3,		ate	Amou Unde Secur	le and unt of rlying ities . 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Nu Deriv Secu Bene Owne Follo Repo Trans (Instr
			Code V	4, and 5) (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		

## Edgar Filing: VALEANT PHARMACEUTICALS INTERNATIONAL - Form 4

## **Reporting Owners**

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
THURMAN RANDY 3300 HYLAND AVENUE COSTA MESA, CA 92626	Х					
Signatures						
By: Michelle May For: Randy Thurman	H.	05/2	25/2005			
<u>**</u> Signature of Reporting Person		]	Date			

## **Explanation of Responses:**

If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Represents award of phantom stock pursuant to the 2003 Equity Incentive Plan, which may be settled only in common stock.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.